Gastrointestinal tolerability of lornoxicam compared to that of naproxen in healthy male volunteers.
OBJECTIVE
Gastrointestinal effects are common adverse effects associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Lornoxicam is a new nonsteroidal anti-inflammatory drug and its gastroduodenal tolerability was compared to that of naproxen in a randomized, double-blind, crossover study.


METHODS
Eighteen healthy male volunteers received lornoxicam 8 mg b.d. or naproxen 500 mg b.d. administered orally over two 7-day dosing periods. Upper endoscopy was performed by two independent investigators at the beginning and end of each dosing regimen.


RESULTS
Lornoxicam 8 mg b.d. caused significantly less mucosal injury than naproxen 500 mg b.d. in the stomach/duodenal bulb, as well as in the mid/distal duodenum.


CONCLUSIONS
These findings may have favourable implications for lornoxicam in the clinical setting, if this dose provides optimal control of arthritic pain.
Aabakken
L
L
Department of Gastroenterology, Ullevål Hospital, Oslo, Norway.
Osnes
M
M
Frenzel
W
W
D000293:Adolescent; D000328:Adult; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects*; D018592:Cross-Over Studies; D004311:Double-Blind Method; D016099:Endoscopy, Gastrointestinal / Q000379:methods; D005753:Gastric Mucosa / Q000187:drug effects; D006801:Humans; D007413:Intestinal Mucosa / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D009288:Naproxen / Q000009:adverse effects*; D010894:Piroxicam / Q000009:adverse effects / Q000031:analogs & derivatives*
D000894:Anti-Inflammatory Agents, Non-Steroidal; D010894:Piroxicam; D009288:Naproxen; C059451:lornoxicam